Lyell Immunopharma (LYEL) News Today $0.48 +0.02 (+3.91%) Closing price 04/23/2025 04:00 PM EasternExtended Trading$0.48 0.00 (-0.21%) As of 04/23/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Johnson & Johnson Buys Shares of 823,317 Lyell Immunopharma, Inc. (NASDAQ:LYEL)Johnson & Johnson purchased a new position in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 823,317 shares of the company's stock, valued at approximately $52April 22 at 6:35 AM | marketbeat.comLyell Immunopharma (NASDAQ:LYEL) Earns Neutral Rating from HC WainwrightHC Wainwright reissued a "neutral" rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a research note on Wednesday.April 18, 2025 | marketbeat.comLyell Immunopharma announces FDA granted RMAT designation to LYL314April 17, 2025 | markets.businessinsider.comLyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell LymphomaApril 15, 2025 | globenewswire.comInsider Buying: Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Purchases 35,640 Shares of StockLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) Director Otis W. Brawley purchased 35,640 shares of the company's stock in a transaction dated Monday, March 31st. The shares were acquired at an average cost of $0.56 per share, for a total transaction of $19,958.40. Following the transaction, the director now owns 35,640 shares of the company's stock, valued at $19,958.40. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.April 4, 2025 | marketbeat.comOtis W. Brawley Buys 35,640 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) StockApril 3, 2025 | insidertrades.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest UpdateLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 5,980,000 shares, a decline of 26.1% from the February 28th total of 8,090,000 shares. Based on an average daily volume of 1,090,000 shares, the days-to-cover ratio is currently 5.5 days. Approximately 4.8% of the shares of the stock are sold short.March 31, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $1.05 Million Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL)Charles Schwab Investment Management Inc. lifted its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 43.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,645,787 shares of the compMarch 31, 2025 | marketbeat.comBank of America Securities Keeps Their Sell Rating on Lyell Immunopharma (LYEL)March 28, 2025 | markets.businessinsider.comIs Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March?March 28, 2025 | insidermonkey.comTakeda Pharmaceutical Co. Ltd. Acquires Shares of 823,317 Lyell Immunopharma, Inc. (NASDAQ:LYEL)Takeda Pharmaceutical Co. Ltd. purchased a new stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 823,317 shares of the company's stock, valued at approximately $527,000. Lyell ImmunMarch 28, 2025 | marketbeat.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Director Sumant Ramachandra Purchases 200,000 SharesLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) Director Sumant Ramachandra purchased 200,000 shares of the firm's stock in a transaction on Friday, March 21st. The stock was acquired at an average price of $0.58 per share, with a total value of $116,000.00. Following the completion of the transaction, the director now owns 200,000 shares in the company, valued at approximately $116,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.March 26, 2025 | marketbeat.comFavourable Signals For Lyell Immunopharma: Numerous Insiders Acquired StockMarch 20, 2025 | finance.yahoo.comInsider Buying: Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Buys 158,000 Shares of StockLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) Director Richard Klausner bought 158,000 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were bought at an average price of $0.60 per share, with a total value of $94,800.00. Following the transaction, the director now owns 843,365 shares of the company's stock, valued at $506,019. The trade was a 23.05 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.March 19, 2025 | marketbeat.comCharles W. Newton Acquires 200,000 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) StockLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) CFO Charles W. Newton bought 200,000 shares of the company's stock in a transaction on Monday, March 17th. The shares were acquired at an average price of $0.56 per share, with a total value of $112,000.00. Following the transaction, the chief financial officer now directly owns 200,000 shares in the company, valued at approximately $112,000. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this link.March 19, 2025 | marketbeat.comLynn Seely Buys 175,000 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) StockLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) CEO Lynn Seely purchased 175,000 shares of the company's stock in a transaction that occurred on Friday, March 14th. The stock was purchased at an average price of $0.61 per share, for a total transaction of $106,750.00. Following the purchase, the chief executive officer now owns 712,500 shares in the company, valued at $434,625. This represents a 32.56 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.March 19, 2025 | marketbeat.comShort Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Declines By 16.2%Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 8,090,000 shares, a drop of 16.2% from the February 13th total of 9,650,000 shares. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is currently 7.0 days. Currently, 6.5% of the shares of the stock are short sold.March 19, 2025 | marketbeat.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Director Richard Klausner Purchases 158,000 SharesMarch 19, 2025 | insidertrades.comHC Wainwright Has Optimistic Outlook of LYEL Q1 EarningsLyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) - Research analysts at HC Wainwright increased their Q1 2025 EPS estimates for Lyell Immunopharma in a report issued on Thursday, March 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.17) per share for the qMarch 17, 2025 | marketbeat.comLyell Immunopharma (NASDAQ:LYEL) Receives Neutral Rating from HC WainwrightHC Wainwright restated a "neutral" rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research note on Thursday.March 14, 2025 | marketbeat.comLyell Immunopharma (NASDAQ:LYEL) Issues Quarterly Earnings ResultsLyell Immunopharma (NASDAQ:LYEL - Get Free Report) released its earnings results on Tuesday. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%.March 12, 2025 | marketbeat.comLyell Immunopharma reports Q4 net loss $45.9M vs. net loss $44M last yearMarch 12, 2025 | markets.businessinsider.comLyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024March 11, 2025 | globenewswire.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Down 16.3% in FebruaryLyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the recipient of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 9,650,000 shares, a drop of 16.3% from the January 31st total of 11,530,000 shares. Approximately 7.7% of the company's shares are sold short. Based on an average trading volume of 1,270,000 shares, the short-interest ratio is presently 7.6 days.March 6, 2025 | marketbeat.comLyell Immunopharma (LYEL) to Release Earnings on WednesdayLyell Immunopharma (NASDAQ:LYEL) will be releasing earnings on Wednesday, February 26.February 19, 2025 | marketbeat.comLyell Immunopharma Announces Participation in Upcoming Investor ConferencesFebruary 18, 2025 | globenewswire.comLyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 46% stakeJanuary 31, 2025 | finance.yahoo.comLyell Immunopharma Faces Nasdaq delisting over share priceJanuary 25, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Lyell Immunopharma (LYEL) and Gilead Sciences (GILD)January 16, 2025 | markets.businessinsider.comLyell Immunopharma price target lowered to 60c from $1 at BofAJanuary 12, 2025 | markets.businessinsider.comLyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare ConferenceJanuary 9, 2025 | globenewswire.comBank of America Securities Sticks to Its Sell Rating for Lyell Immunopharma (LYEL)January 7, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and Lyell Immunopharma (LYEL)December 24, 2024 | markets.businessinsider.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Shares Sold by Fmr LLCFmr LLC cut its stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 62.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,024,583 shares of the company's stock after selling 1,708,879 shares during the quaDecember 16, 2024 | marketbeat.comLyell Immunopharma Inc Ordinary SharesDecember 12, 2024 | morningstar.comLyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual MeetingDecember 9, 2024 | globenewswire.comMitchell Kapoor Maintains Hold Rating on Lyell Immunopharma Amid Promising IMPT-314 Results and Market ChallengesNovember 13, 2024 | markets.businessinsider.comThe Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 ExpertsNovember 12, 2024 | benzinga.comHC Wainwright Reaffirms Neutral Rating for Lyell Immunopharma (NASDAQ:LYEL)HC Wainwright reaffirmed a "neutral" rating and issued a $1.00 price target on shares of Lyell Immunopharma in a report on Tuesday.November 12, 2024 | marketbeat.comLyell Immunopharma reports Q3 net loss $44.6M vs. $50.9M last yearNovember 9, 2024 | markets.businessinsider.comLyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024November 8, 2024 | markets.businessinsider.comLyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual MeetingNovember 5, 2024 | globenewswire.comLyell shares down as BofA double downgrades to SellNovember 1, 2024 | msn.comLyell Immunopharma’s Strategic Moves and Leadership ExpansionNovember 1, 2024 | markets.businessinsider.comLyell Immunopharma Completes Acquisition of ImmPACT BioOctober 31, 2024 | globenewswire.comLyell Immunopharma double downgraded to Underperform at BofA after reorgOctober 31, 2024 | markets.businessinsider.comLyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition StrategyOctober 31, 2024 | benzinga.comB of A Securities Downgrades Lyell Immunopharma (LYEL)October 31, 2024 | msn.comLyell cut to underperform by BofA, pipeline reorganization citedOctober 31, 2024 | msn.comBank of America Downgrades Lyell Immunopharma (NASDAQ:LYEL) to UnderperformBank of America downgraded shares of Lyell Immunopharma from a "buy" rating to an "underperform" rating and lowered their price target for the stock from $6.00 to $1.00 in a report on Wednesday.October 30, 2024 | marketbeat.com Get Lyell Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter. Email Address LYEL Media Mentions By Week LYEL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LYEL News Sentiment▼0.940.72▲Average Medical News Sentiment LYEL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LYEL Articles This Week▼31▲LYEL Articles Average Week Get Lyell Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OPT News COGT News KROS News IMTX News ARVN News QURE News BCYC News URGN News GHRS News KURA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LYEL) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredA Biotech Power Move? This company is leading the charge in developing advanced antiviral therapies—watch closely!With a revolutionary antiviral drug, this company is in a great position to build shareholder value as this ti...Smallcaps Daily | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyell Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LYEL Stock Free LYEL Stock Alerts